. 2010 Oct 11;105(5):568–575. doi: 10.1093/bja/aeq270

Table 1.

Strategies considered in the economic assessment

Where a ‘can't intubate, can't ventilate’ event occurs:

succinylcholine (1 mg kg⁻¹)-induced neuromuscular block followed by spontaneous recovery
rocuronium (1.2 mg kg⁻¹)-induced neuromuscular block followed by immediate reversal using sugammadex 16 mg kg⁻¹

Where a ‘can't intubate, can't ventilate’ event does not occur and the subsequent procedure is very short:

succinylcholine (1 mg kg⁻¹)-induced neuromuscular block (for rapid induction and to maintain block throughout the procedure) followed by spontaneous recovery
rocuronium (1.2 mg kg⁻¹)-induced neuromuscular block (for rapid induction and to maintain block throughout the procedure) followed by reversal using sugammadex 4 mg kg⁻¹

Where a ‘can't intubate, can't ventilate’ event does not occur and the subsequent procedure is short (<60 min) or requires profound block throughout:

succinylcholine (1 mg kg⁻¹)-induced neuromuscular block (for rapid induction) followed by rocuronium (0.6 mg kg⁻¹)-induced neuromuscular block (to maintain block throughout the procedure) followed by reversal using neostigmine (2.5 mg) with glycopyrrolate (0.5 mg)
rocuronium (1.2 mg kg⁻¹)-induced neuromuscular block (for rapid induction and to maintain block throughout the procedure) followed by reversal using sugammadex 4 mg kg⁻¹

Where a ‘can't intubate, can't ventilate’ event does not occur and the subsequent procedure is long (>60 min) and does not require profound block throughout:

succinylcholine (1 mg kg⁻¹)-induced neuromuscular block (for rapid induction) followed by rocuronium (0.6 mg kg⁻¹)-induced neuromuscular block (to maintain block throughout the procedure) followed by reversal using neostigmine (2.5 mg) with glycopyrrolate (0.5 mg)
rocuronium (1.2 mg kg⁻¹)-induced neuromuscular block (for rapid induction and to maintain block throughout the procedure) followed by reversal using sugammadex 2 mg kg⁻¹